Optimizing oncology drug development: systematic review of 22 years of myeloma randomized controlled trials

doi:10.1093/jnci/djaf326

Return

Optimizing oncology drug development: systematic review of 22 years of myeloma randomized controlled trials

2025-11-09

Rajshekhar Chakraborty

Edward R Scheffer Cliff, MBBS

Ghulam Rehman Mohyuddin *

DOI：10.1093/jnci/djaf326

Original

Save

View PDF

Abstract

En 中文

Although myeloma represents a key success story in oncology, some drugs have failed to meet primary endpoints in randomized controlled trials (RCTs), despite promising early phase activity. This analysis aimed to understand factors that increase the likelihood of meeting primary endpoints in myeloma RCTs.

Keywords:

myeloma

randomized controlled trials

drug development

clinical trials

oncology

AI Summary

Key information extracted from the uploaded paper, including a brief overview, abstract, background, key highlights, visual analysis, and future outlook.